acosamide and levetiracetam in partial epilepsy

Phase 3

Recruiting

• Conditions: drug Resistant partial epilepsy.; Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable; G40.01

• Registration Number: IRCT20210925052579N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients with resistant partial onset epilepsy
written informed consent
age more than 18 years

Exclusion Criteria

cardiac arrhythmias for lacosamide group
pregnancy for lacosamide group
renal failure for levetiracetam group
mood disorders for levetiracetam group

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of seizures in resistant partial onset epilepsy. Timepoint: Three months before the intervention, 1, 2 and 3 months after taking the drug. Method of measurement: questionnaire.;Abnormal changes in the electroencephalogram. Timepoint: before the intervention and 3 months after taking drugs. Method of measurement: taking electroencephalogram.

Secondary Outcome Measures

Name	Time	Method
Drug side effects after taking lacosamide and levetiracetam. Timepoint: Within three months after starting the drug. Method of measurement: questionnaire.